small cell lung cancer

News

Amgen's BiTE for lung cancer backed for EU approval

Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

Digital

BIO-Europe Spring interview with Dr Olga Nissan

On collaboration, computational chemistry, and cutting-edge ...

Oncology

pharmaphorum podcast Episode 211, ESMO25: Boehringer Ingelheim

ESMO25: Patient-centric oncological futures with Boehringer ...

On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.

News

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

News

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

News

Mixed data from lung cancer trials on show at WCLC

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

Amgen's BiTE for lung cancer backed for EU approval

On collaboration, computational chemistry, and cutting-edge ...

ESMO25: Patient-centric oncological futures with Boehringer ...

Jazz, Roche combo cleared by FDA for lung cancer

Imfinzi becomes first NHS drug for aggressive lung cancer

Mixed data from lung cancer trials on show at WCLC

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

small cell lung cancer

Editor's Picks